ScreenerHero

NNVC NanoViricides, Inc.

AMEX · US · Healthcare · Biotechnology · nanoviricides.com
1.310USD-9.03%Mkt Cap: 33.44M $P/E: —

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap33.44M USD
Enterprise Value32.94M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-9.47M USD
Revenue/Share—
Last Price1.310 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.00
PEG—
EV/EBITDA-4.23
EV/Revenue—
P/S—
P/B3.31
EPS (TTM)-0.40
EPS (Forward)-0.35
52W Range
0.850033% of range2.230
52W High2.230 USD
52W Low0.8500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-125.93%
ROA-107.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.48M USD
CapEx (TTM)56.96K USD
FCF Margin—
FCF Yield-14.22%
Net Debt-2.79M USD
Net Debt/EBITDA0.36
Balance Sheet
Debt/Equity—
Current Ratio2.66
Quick Ratio2.35
Book Value/Sh0.42 USD
Cash/Share0.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateSep 24, 2019
Splits
Last Split1:20
Split DateSep 24, 2019
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.000 USD
Upside (mean)+358.0%
Target Range6.000 USD – 6.000 USD
# Analysts2
Ownership
Shares Out.25.52M
Float24.92M
Insiders2.49%
Institutions9.29%
Short Interest
Short Ratio1.7d
Short % Float2.36%
Short % Out.2.30%
Shares Short587.62K
Short (prev mo.)874.09K
Technical
SMA 501.338 (-2.1%)
SMA 2001.272 (+3.0%)
Beta1.79
S&P 52W Chg15.77%
Avg Vol (30d)464.38K
Avg Vol (10d)565.52K
Technical Indicators
RSI (14)48.3
MACD0.0166
MACD Signal0.0078
MACD Hist.+0.0088
BB Upper1.649 USD
BB Middle1.301 USD
BB Lower0.9533 USD
BB Width53.45%
ATR (14)0.1269 USD
Vol Ratio (20d)0.52x